ATENOLOL LACTATION STUDY

阿替洛尔哺乳期研究

• 批准号: 7603464
• 负责人: MARY F HEBERT
• 金额: $ 0.17万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603464
• 关键词: Academy; Adverse effects; American; Atenolol; Bradycardia; Breast Feeding; Computer Retrieval of Information on Scientific Projects Database; Condition; Discipline of Nursing; Drug Kinetics; Exclusive Breastfeeding; Exercise; Funding; Grant; Health Benefit; High Blood Pressure; Human; Human Milk; Hypertension; Impaired Renal Function; Infant; Institution; Lactation; Life; Pediatrics; Plasma; Postpartum Period; Pregnancy; Pregnant Women; Premature Infant; Product Labeling; Reporting; Research; Research Personnel; Resources; Source; Therapeutic; United States National Institutes of Health; Urine; Week; Woman; World Health Organization; clinically significant; design

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. High blood pressure is a common condition in pregnant women. Atenolol is an effective agent for the management of high blood pressure during and after pregnancy. We recently completed a study evaluating the pharmacokinetics of atenolol in pregnancy. However, no one has studied the pharmacokinetics of atenolol postpartum. Product labeling for atenolol states that "Atenolol is excreted in human breast milk at a ratio of 1.5 to 6.8 when compared to the concentration in plasma. Caution should be exercised when atenolol is administered to a nursing woman. Clinically significant bradycardia has been reported in breast fed infants. Premature infants, or infants with impaired renal function, may be more likely to develop adverse effects." Despite this warning, many women receiving atenolol for hypertension decide to breastfeed their infants. Because of the multiple health benefits for infants, exclusive breastfeeding for the first 6 months of life is recommended by the American Academy of Pediatrics and the World Health Organization. This study is designed to evaluate the pharmacokinetics of atenolol in plasma, urine and breast milk 2-4 weeks, 3-4 months and 6-8 months postpartum in women taking atenolol for therapeutic reasons and nursing their infants.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 高血压是孕妇的常见病。 阿替洛尔是治疗妊娠期间和妊娠后高血压的有效药物。 我们最近完成了一项评估阿替洛尔在妊娠期药代动力学的研究。 然而，没有人研究阿替洛尔产后的药代动力学。阿替洛尔的产品标签指出，“与血浆浓度相比，阿替洛尔以 1.5 至 6.8 的比例排泄到人乳中。给哺乳期妇女服用阿替洛尔时应小心。据报道，乳腺会出现临床上显着的心动过缓。”喂养过的婴儿或肾功能受损的婴儿可能更容易出现不良反应。” 尽管有这一警告，许多接受阿替洛尔治疗高血压的妇女还是决定母乳喂养她们的婴儿。 由于对婴儿的多种健康益处，美国儿科学会和世界卫生组织建议在生命的前 6 个月进行纯母乳喂养。 本研究旨在评估因治疗原因服用阿替洛尔并哺乳婴儿的女性产后 2-4 周、3-4 个月和 6-8 个月血浆、尿液和母乳中阿替洛尔的药代动力学。